JACC Cardiovasc Imaging by Wu, Melinda D. et al.
Lipoprotein Apheresis Acutely Reverses Coronary Microvascular 
Dysfunction in Patients With Severe Hypercholesterolemia
Melinda D. Wu, MDa,b,*, Federico Moccetti, MDa,*, Eran Brown, BSa, Brian P. Davidson, 
MDa,c, Tamara Atkinson, MDa,c, J. Todd Belcik, ACS, RDCSa, George Giraud, MD, PhDa,c, P. 
Barton Duell, MDa, Sergio Fazio, MD, PhDa, Hagai Tavori, PhDa, Sotirios Tsimikas, MDd, 
Jonathan R. Lindner, MDa,e
aKnight Cardiovascular Institute, Oregon Health & Science University, Portland, Oregon
bDoernbecher Children’s Hospital, Oregon Health & Science University, Portland, Oregon
cPortland Veterans Administration Hospital, Oregon Health & Science University, Portland, 
Oregon
dCardiovascular Division, University of California, San Diego, San Diego, California
eOregon National Primate Research Center, Oregon Health & Science University, Portland, 
Oregon.
Abstract
OBJECTIVES—The study evaluated whether lipoprotein apheresis produces immediate changes 
in resting perfusion in subjects with severe hypercholesterolemia, and whether there is a difference 
in the response between peripheral and coronary microcirculations.
BACKGROUND—Lipoprotein apheresis is used in patients with severe hypercholesterolemia to 
reduce plasma levels of low-density lipoprotein cholesterol.
METHODS—Quantitative contrast-enhanced ultrasound perfusion imaging of the myocardium at 
rest and skeletal muscle at rest and during calibrated contractile exercise was performed before 
and immediately after lipoprotein apheresis in 8 subjects with severe hypercholesterolemia, 7 of 
whom had a diagnosis of familial hypercholesterolemia. Myocardial perfusion imaging was also 
performed in 14 normal control subjects. Changes in myocardial work and left ventricular function 
were assessed by echocardiography. Ex vivo ovine coronary and femoral artery ring tension assays 
were assessed in the presence of pre- and post-apheresis plasma.
RESULTS—Apheresis acutely decreased low-density lipoprotein cholesterol (234.9 ± 103.2 
mg/dl vs. 67.1 ± 49.5 mg/dl; p < 0.01) and oxidized phospholipid on apolipoprotein B-100 (60.2 
± 55.2 nmol/l vs. 47.0 ± 24.5 nmol/l; p = 0.01), and acutely increased resting myocardial perfusion 
(55.1 [95% confidence interval: 77.2 to 73.1] vs. 135 [95% confidence interval: 81.2 to 189.6] 
IU/s; p = 0.01), without changes in myocardial work. Myocardial longitudinal strain improved in 
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those subjects with reduced pre-apheresis function. Skeletal muscle perfusion at rest and during 
contractile exercise was unchanged by apheresis. Acetylcholine-mediated dilation of ex vivo ovine 
coronary but not femoral arteries was impaired in pre-apheresis plasma and was completely 
reversed in post-apheresis plasma.
CONCLUSIONS—Lipoprotein apheresis produces an immediate improvement in coronary 
microvascular function, which increases myocardial perfusion and normalizes endothelial-
dependent vasodilation. These changes are not observed in the periphery. (Acute Microvascular 
Changes With LDL Apheresis; NCT02388633).
Keywords
apheresis; contrast ultrasound; familial hypercholesterolemia; myocardial contrast 
echocardiography
In patients with severe hypercholesterolemia, including those with familial 
hypercholesterolemia (FH), statins are the first-line approach for lowering low-density 
lipoprotein cholesterol (LDL-C) and reducing risk for major adverse acute or chronic 
ischemic complications (1). Myocardial ischemia with hypercholesterolemia may be 
mediated not only by obstructive atherosclerotic disease, but also by abnormal microvascular 
function that occurs from vasoconstrictor/vasodilator imbalance or to abnormal 
microvascular rheology (2–5).
Lipoprotein apheresis is a therapeutic option for patients with severe hypercholesterolemia 
in whom adequate LDL-C cannot be achieved with maximally tolerated pharmacotherapy 
(3,6,7). Although apheresis is intended to reduce risk for atherothrombotic events, the partial 
removal of LDL-C or other lipoprotein particles could potentially improve microvascular 
function by reducing oxidative and inflammatory mediators, restoring vasomotor balance, 
and improving rheology (3,6). There are conflicting results regarding whether apheresis in 
patients with FH improves endothelial-dependent vasodilation in large peripheral arteries 
(8,9). Improvement in coronary Doppler-derived flow reserve has been more consistent 
(10,11), although in some studies flow reserve was increased by apheresis not by 
augmentation of hyperemic flow, but rather by reduction in resting flow, possibly reflecting 
changes in myocardial oxygen demand (10).
In this study, we used myocardial contrast echocardiography (MCE) and skeletal muscle 
contrast-enhanced ultrasound (CEU) to test whether resting microvascular perfusion is 
increased immediately after lipoprotein apheresis in subjects with severe 
hypercholesterolemia, and whether the peripheral and coronary microcirculations differ in 
their response. Further mechanistic insight was provided by evaluation of coronary and 
peripheral arterial endothelial-dependent vasodilation in the presence of pre- and post-
apheresis plasma, and examination of acute changes in oxidatively modified phospholipids 
(OxPL) and blood rheology.
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METHODS
PATIENT POPULATION AND PROTOCOL.
The study was approved by the Institutional Review Board at Oregon Health & Science 
University (NCT02388633). We recruited 8 patients with a diagnosis of severe 
hypercholesterolemia, 7 of whom had a diagnosis of FH, who were undergoing first or 
recurrent lipoprotein apheresis in whom diet, lifestyle modification, and maximum drug 
therapy was ineffective or not tolerated. Exclusion criteria included pregnant or lactating 
women, large right-to-left shunt, left ventricular ejection fraction <40%, or more than mild 
valve regurgitation or stenosis. Subjects were studied immediately before, and again within 2 
h after completion of extracorporeal lipoprotein apheresis performed with dextran sulfate 
adsorption (Liposorber LA-15, Kaneka, Osaka, Japan). Comprehensive transthoracic 
echocardiography was conducted to evaluate left and right ventricular function. Blood was 
drawn for determination of plasma lipids, plasma viscosity, and erythrocyte deformability. 
Quantitative ultrasound perfusion imaging was used to assess resting myocardial blood flow 
as well as forearm skeletal muscle blood flow at rest and during moderate-intensity 
contractile exercise. Myocardial perfusion imaging data from 14 age-matched control 
patients without any coronary artery disease on coronary computed tomography angiography 
were also included for analysis.
LIPID AND OxPL ANALYSIS.
See the Online Appendix.
ECHOCARDIOGRAPHY.
Echocardiography (iE33, Philips Ultrasound, Andover, Massachusetts) was performed to 
assess chamber dimensions according to guidelines published by the American Society of 
Echocardiography (12). EF was calculated using the modified Simpson’s method. Stroke 
volume was calculated using the product of left ventricular outflow tract area and the time-
velocity integral measured by pulsed-wave spectral Doppler. Myocardial work was 
calculated by the product of stroke volume index, systolic blood pressure, and heart rate. 
Arterial elastance as a measure of afterload was calculated by: (0.9 × systolic blood 
pressure)/(stroke volume index). Systemic vascular resistance was calculated by the 
difference in mean blood pressure and right atrial pressure estimated by inferior vena cava 
imaging divided by cardiac output (product of stroke volume and heart rate). Global 
longitudinal strain (GLS) was measured offline (Epsilon Imaging, Ann Arbor, Michigan) 
from DICOM image sets using speckle-tracking echocardiography of the LV from long-axis 
views.
CONTRAST-ENHANCED ULTRASOUND.
Perfusion imaging was performed with a multipulse contrast-specific detection algorithm 
(amplitude modulation imaging) at 1.6 MHz and a mechanical index of 0.12. Lipid-shelled 
octafluoropropane microbubbles (Definity, Lantheus Medical Imaging, North Billerica, 
Massachusetts) were diluted 1:15 in normal saline and infused intravenously at a rate of 
0.375 ml/min for obtaining blood pool signal from the brachial artery while gating 
Wu et al. Page 3
JACC Cardiovasc Imaging. Author manuscript; available in PMC 2020 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
acquisition (1 Hz) to end-diastole. For MCE, the infusion rate was increased to 1 ml/min. 
The heart was imaged in the apical 4- and 3-chamber views, and frames triggered to end-
systole by electrocardiography gating were obtained after a 5-frame high-power (mechanical 
index >0.9) pulse sequence. For muscle CEU, the infusion rate was increased to 1.5 ml/min. 
The proximal forearm flexor muscle group was imaged in the transaxial plane and frames 
were acquired gated to end-diastole after a destructive pulse sequence. Image acquisition 
was repeated immediately after 1 min of high-intensity exercise performed by handgrip at 
0.2 Hz on a calibrated ergometer (Detecto Scales, Inc., Webb City, Missouri) at 75% of their 
predetermined maximal force. For assessing perfusion, regions of interest were placed over 
2 myocardial regions representing 2 separate coronary artery territories for the heart, and 
over the proximal forearm flexor muscle groups for skeletal muscle. The first post-
destructive frame was digitally subtracted from all subsequent frames and background-
subtracted time-intensity data were fit to the following function:
y = A 1 − e−βt
where y is signal intensity at time t, A is the plateau intensity reflecting relative 
microvascular blood volume (MBV), and β is the rate constant reflecting microvascular 
blood flux rate (13). Microvascular blood flow was quantified by the product of MBV and β 
(13). For skeletal muscle perfusion imaging, assessment for only the distal microvascular 
compartment (capillaries and small arterioles and venules) was made by digitally subtracting 
frames obtained 1 s after the post-destructive pulse sequence, which eliminates large 
intramuscular vessels (14).
BLOOD RHEOLOGY.
See the Online Appendix.
PERIPHERAL AND CORONARY ARTERIAL ENDOTHELIAL-DERIVED VASODILATION.
An ex vivo arterial ring tension assay was used to assess vascular reactivity to acetylcholine 
(Ach) in the presence of plasma obtained before or after apheresis. See the Online Appendix 
for methods.
NO PRODUCTION.
See the Online Appendix.
STATISTICAL METHODS.
Data were analyzed using Prism version 6.0 (GraphPad Software, La Jolla, California). 
Normal versus non-normal distribution of data was determined by the D’Agostino-Pearson 
omnibus test. For non-normally distributed data, a Wilcoxon rank sum test was used to 
compare pre- and post-apheresis data, while a Mann-Whitney test was used to test apheresis 
patients to control subjects. For normally distributed data, paired Student’s t-tests were used. 
Linear regression analysis was used to evaluate correlations between lipid and perfusion 
data. Differences in Ach dose-response were assessed by comparison of individual half 
maximal inhibitory concentration values. Numerical values are listed as mean ± SD or as 
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median (95% confidence interval), unless stated otherwise; differences were considered 
significant at p < 0.05 (2-sided).
RESULTS
CLINICAL DATA, LIPID LEVELS, AND BLOOD RHEOLOGY.
The indication for lipoprotein apheresis in this cohort was inability to achieve LDL-C goal 
with maximally tolerated LDL-C-lowering therapy in all subjects. Three subjects were not 
taking a statin due to severe intolerance, but were on other lipid-lowering medications. 
Demographic and clinical data are presented in Table 1. Three of the subjects were studied at 
the time of their first lipoprotein apheresis treatment while the remaining subjects were 
studied an average of 27 ± 8 days after their previous recurrent apheresis treatment.
Lipoprotein apheresis resulted in reductions in total cholesterol (325.1 ± 118.8 mg/dl vs. 
135.8 ± 55.4 mg/dl; p < 0.01), non–high-density lipoprotein cholesterol (273.5 ± 118.9 
mg/dl vs. 86.4 ± 56.2 mg/dl; p < 0.01), LDL-C (234.9 ± 103.2 mg/dl vs. 67.1 ± 49.5 mg/dl; 
p < 0.01), and Lipoprotein(a) (71.3 ± 55.2 mg/dl vs. 19.9 ± 14.6 mg/dl; p < 0.05) (Figure 1). 
The concentration of OxPL-apolipoprotein B-100 (apo B-100) lipoproteins was reduced on 
average by 24 ± 17% (60.2 ± 55.2 nmol/l vs. 47.0 ± 24.5 nmol/l; p = 0.01). Apheresis 
significantly and uniformly increased erythrocyte deformability and decreased plasma 
viscosity (Figure 2).
HEMODYNAMIC AND ECHOCARDIOGRAPHIC DATA.
There were no significant differences in heart rate, blood pressure, or double product before 
and after apheresis (Table 2). Similarly, there were no significant changes in calculated 
stroke volume, cardiac output, myocardial work, arterial elastance, systemic vascular 
resistance, or indexes of contractility (LV end-systolic pressure-volume relation) after 
apheresis. Although LV longitudinal strain improved in all 4 subjects with reduced strain at 
baseline (defined as GLS >−0.17) (−14.4 ± 2.2 to −18.0 ± 4.1), there was no change in those 
with normal pre-apheresis strain, resulting in no significant difference for the group as a 
whole (Table 2).
SKELETAL MUSCLE AND MYOCARDIAL MICROVASCULAR PERFUSION.
Lipoprotein apheresis did not significantly change skeletal muscle perfusion or any of the 
parametric components of MBV (A-value) or microvascular flux rate (β–value) when 
measured either at rest or during exercise (Figure 3). This finding persisted when image 
analysis was performed to eliminate all but the very distal microcirculation (microvessels 
with mean blood velocity <4 mm/s) (Online Figure 1). Pre-apheresis resting skeletal muscle 
CEU perfusion imaging values were found to be similar without significant differences to 
values from normal control populations studied previously (15).
In contrast, apheresis significantly increased resting myocardial blood flow (Figure 4). The 
greatest increases in flow occurred in those undergoing apheresis for the first time (Online 
Figure 2). The increase in perfusion was attributable to improvements in both myocardial 
microvascular flux rate and MBV. On average, the increase in myocardial blood flow tended 
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to be greater in the 3 subjects undergoing apheresis for the first time (342 ± 257%) 
compared with those undergoing recurrent apheresis (86 ± 101%), but the difference was not 
statistically significant. Pre-apheresis parameters of myocardial microvascular perfusion 
were all significantly lower than in age-matched control subjects and skeletal muscle blood 
flow during exercise approximated that of myocardial blood flow, suggesting that 
improvements in rheology, which should affect perfusion similarly in the 2 tissues, were not 
solely responsible for the increases in flow that were unique to the myocardium.
CORRELATIONS BETWEEN LIPID VALUES AND MYOCARDIAL PERFUSION.
Although the small number of subjects limited statistical power, the apheresis-related change 
in microvascular flux rate was modestly correlated with certain baseline pre-apheresis lipid 
values including cholesterol (r = 0.70; p = 0.05), LDL-C (r = 0.70; p = 0.05), and OxPL-apo 
B-100 (r = 0.75; p = 0.03) (Online Table 1). There were no significant correlations found 
between change in myocardial perfusion and the degree of change in any of the lipid values 
or rheologic parameters. When combining all pre- and post-apheresis data, there was a 
significant but modest inverse correlation between OxPL-apo B-100 and myocardial 
perfusion (microvascular flux rate), but not for any other lipid variable including LDL-C 
(Figure 5).
VASCULAR REACTIVITY.
Vascular reactivity to the endothelium-dependent vasodilator Ach was tested in isolated 
ovine coronary and peripheral artery rings in the presence of plasma obtained pre- and post-
apheresis. Reduction in arterial tension in response to Ach was entirely abolished by 
inhibition of endothelial nitric oxide synthase (eNOS) with L-nitroarginine methyl ester (100 
μmol/l) (Online Figure 3). For coronary arteries, Ach-mediated relaxation (but not relaxation 
with sodium nitroprusside) was reduced in the presence of pre-apheresis plasma and was 
restored completely in the presence of post-apheresis plasma (Figure 6A, Online Figure 3).
Vasoreactivity for femoral artery rings was not different in the presence of pre- or post-
apheresis plasma (Figure 6B). Production of NO by endothelial cells in vitro measured by 
4,5-diaminofluorescein diacetate-2 intensity was substantially lower after cells were exposed 
to pre-apheresis versus post-apheresis plasma (Figures 6C and 6D).
DISCUSSION
Severe hypercholesterolemia has been implicated as a cause of microvascular dysfunction 
through pathways that include reduced bioavailability of endothelial-derived vasodilators, 
increased oxidative signaling, enhanced vasoconstrictor pathway signaling, and increased 
effective viscosity at the capillary level (2,16–19). Evaluation of the severity of 
microvascular dysfunction in FH and whether it is improved by drug or apheresis therapy 
has generally involved the assessment of flow reserve, or of flow-dependent vasodilation in a 
peripheral artery as an indicator of endothelial NO production. In this study, by using 
quantitative perfusion imaging we have demonstrated for the first time that lipoprotein 
apheresis in patients with severe hypercholesterolemia results in an immediate increase in 
resting myocardial perfusion to a level similar to that in control subjects. These beneficial 
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effects on myocardial perfusion, which could not be attributed to changes in myocardial 
work, were not observed for the peripheral microcirculation.
In humans and other large mammals, mechanisms that control microvascular tone vary 
according to vascular hierarchy (20). Shear-dependent arterial responses, which are known 
to be influenced by LDL-C levels (5), tend to predominate in larger arterioles (>100 μm). 
Metabolic mediators such as adenosine, adenosine triphosphate, H2O2, and prostanoids that 
are influenced by inflammatory status, oxidative stress, sympathetic tone, and other factors 
tend to act in smaller precapillary arteriolar networks. Rheological properties such as 
erythrocyte deformability and viscosity, which are influenced by plasma lipoprotein 
concentration, are most impactful at the capillary level (21). In the current study, quantitative 
CEU perfusion imaging was used to evaluate tissue perfusion at the capillary level and, 
accordingly, to assess the net vascular effects of apheresis. Parametric analysis helped 
identify the potential mechanisms by which apheresis affected the myocardial 
microcirculation. The largest increases in resting myocardial flow were found in those 
undergoing apheresis for the first time, in whom large increases in microvascular flux rate 
(β) occurred, implying either a major reduction in tone at the resistance arteriolar level or 
improvement in rheology (22,23).
CEU also provided the unique opportunity to compare responses within myocardial and 
skeletal muscle microcirculations nearly simultaneously, and to assess muscle perfusion 
during physiological hyperemia produced by exercise. Our results indicate that lipoprotein 
apheresis increased resting myocardial perfusion but, unexpectedly, there was no effect on 
forearm muscle perfusion even during exercise. During contractile exercise, muscle blood 
flow and flux rate (β) approximated that seen in the resting myocardium after apheresis. As 
differences in coronary and skeletal muscle capillary diameter are negligible (24), one can 
conclude that improvement in rheology (viscosity and erythrocyte deformability) after 
apheresis was not the primary reason for improving myocardial perfusion because it should 
have produced a similar benefit in exercising skeletal muscle. Our finding that apheresis did 
not affect muscle perfusion is different from a prior study using plethysmography to evaluate 
response to Ach (25). In the prior study, flow augmentation with Ach increased 4- to 5-fold 
compared with the 20-fold increase during exercise in our study. Because NO-dependent 
pathways account for only a small component of muscle vascular response to exercise (26), 
we believe that our findings more accurately reflect a physiological response, whereas the 
prior study tested 1 pathway. By performing echocardiography immediately before MCE, 
we were also able to exclude the possibility that apheresis-related increases in myocardial 
perfusion were a consequence of changes in myocardial work or contractility.
The most plausible explanation for differences in coronary and peripheral microvascular 
response to apheresis is that they respond differently to severe hypercholesterolemia. 
Previous studies have suggested that endothelial-dependent vasomotor response and other 
vasodilator/vasoconstrictor responses are not tightly correlated between the 2 beds (27,28). 
We investigated endothelial-derived pathways based largely on a preponderance of data 
indicating impaired NO signaling in hypercholesterolemia (5,11,17,25). Arterial ring tension 
assays confirmed abnormal endothelial-dependent vasodilation in the presence of pre-
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apheresis plasma for coronary but not femoral artery rings, with complete normalization of 
vasodilation in the presence of post-apheresis plasma.
Potential reasons for abnormal NO-dependent vasomotion in association with dyslipidemia 
include reduced L-arginine transport; reduced eNOS phosphorylation; increased production 
of eNOS inhibitors such as asymmetric dimethylarginine; and the end results of increased 
oxidative stress including uncoupling of eNOS, reduced activity of tetrahydrobiopterin, and 
oxidative metabolism of NO (4,16). Our results with 4,5-diaminofluorescein diacetate-2 
suggested a role of reduced production of NO after exposure to pre-apheresis plasma. 
Inactivation of NO through oxidative modification could have also contributed to reduced 
coronary vasomotion, a notion supported by the reduction in OxPL-apo B-100 by apheresis. 
Prior studies have demonstrated that reduction in oxidatively modified LDL improves 
arterial response to Ach (29) and that apheresis for elevated Lipoprotein(a), which contains 
the highest proportion of OxPL among lipoproteins, reduces angina and improves 
myocardial blood flow during vasodilator stress (30). In a recent study examining 
proangiogenic growth factor gene therapy in patients with refractory angina, improvement in 
resting myocardial blood flow was inversely correlated with OxPL-apo B-100, suggesting 
that patients with low OxPL have the greatest potential for improvement (31). Our own 
findings that baseline pre-apheresis OxPL-apo B-100 levels correlated inversely with 
improvement in myocardial perfusion and that OxPL-apo B-100 from all stages correlated 
with myocardial perfusion suggest a potential role of oxidative stress in governing 
myocardial perfusion.
STUDY LIMITATIONS.
The number of patients was small despite studying all patients undergoing apheresis in our 
institution over a 2-year period willing to participate. However, the magnitude of the 
treatment effects was greater than that anticipated by initial power calculations and obviated 
the need for a larger study. We did not restudy patients sequentially after apheresis to 
determine the rate at which improvement in myocardial perfusion is lost. Although our strain 
echocardiography data suggests apheresis can improve LV function in those with subtle pre-
apheresis dysfunction, we cannot verify this finding based on the small number of subjects 
studied and inconsistent changes in GLS in the group as a whole. It should be noted that ex 
vivo tension studies were performed in large arteries rather than for microvascular 
preparations. However, our primary outcome data from CEU primarily reflect changes that 
occur at the microvascular level. In our study, apheresis was performed with the charge-
based adsorption method, so it is uncertain if other apheresis approaches would produce the 
same results.
In summary, we have demonstrated that lipoprotein apheresis produces an immediate 
coronary-specific improvement in resting myocardial perfusion which is likely secondary to 
changes in the regulation of microvascular tone, which does not occur for skeletal muscle 
even during contractile exercise. It will important to determine whether improvements in 
resting myocardial perfusion are related to improvement in symptoms or to the reduction in 
circulating inflammatory markers.
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Ach acetylcholine
apo B apolipoprotein B-100
CEU contrast-enhanced ultrasound
Enos endothelial nitric oxide synthase
FH familial hypercholesterolemia
GLS global longitudinal strain
LDL-C low-density lipoprotein cholesterol
MBV microvascular blood volume
MCE myocardial contrast echocardiography
OxPL oxidatively modified phospholipids
REFERENCES
1. Besseling J, Hovingh GK, Huijgen R, Kastelein JJ, Hutten BA. Statins in familial 
hypercholesterolemia: consequences for coronary artery disease and all-cause mortality. J Am Coll 
Cardiol 2016;68:252–60. [PubMed: 27417002] 
2. Bender SB, de Beer VJ, Tharp DL, et al. Severe familial hypercholesterolemia impairs the 
regulation of coronary blood flow and oxygen supply during exercise. Basic Res Cardiol 
2016;111:61. [PubMed: 27624732] 
3. Mellwig KP, Pulawski E, Horstkotte D, van Buuren F. Lipid apheresis: oxidative stress, rheology, 
and vasodilatation. Clin Res Cardiol Suppl 2012;7:45–9. [PubMed: 22528131] 
4. Landmesser U, Hornig B, Drexler H. Endothelial dysfunction in hypercholesterolemia: mechanisms, 
pathophysiological importance, and therapeutic interventions. Semin Thromb Hemost 2000;26: 
529–37. [PubMed: 11129409] 
5. Creager MA, Cooke JP, Mendelsohn ME, et al. Impaired vasodilation of forearm resistance vessels 
in hypercholesterolemic humans. J Clin Invest 1990;86:228–34. [PubMed: 2195060] 
Wu et al. Page 9
JACC Cardiovasc Imaging. Author manuscript; available in PMC 2020 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
6. Rossenbach J, Mueller GA, Lange K, et al. Lipid-apheresis improves microcirculation of the upper 
limbs. J Clin Apher 2011;26:167–73. [PubMed: 21500250] 
7. Gordon BR, Kelsey SF, Dau PC, et al. Long-term effects of low-density lipoprotein apheresis using 
an automated dextran sulfate cellulose adsorption system. Liposorber Study Group. Am J Cardiol 
1998;81:407–11.
8. Lu Q, Eriksson M, Jogestrand T, Henriksson P, Freyschuss A. Micro- and macrocirculatory effects 
of apheresis in patients with familial hyperlipidemia. Ther Apher Dial 2003;7:115–8. [PubMed: 
12921126] 
9. Ellins EA, New KJ, Datta DB, et al. Validation of a new method for non-invasive assessment of 
vasomotor function. Eur J Prev Cardiol 2016;23: 577–83. [PubMed: 26209709] 
10. Kobayashi K, Yamashita K, Tasaki H, et al. Evaluation of improved coronary flow velocity reserve 
using transthoracic Doppler echocardiography after single LDL apheresis. Ther Apher Dial 
2004;8:383–9. [PubMed: 15663533] 
11. Igarashi K, Tsuji M, Nishimura M, Horimoto M. Improvement of endothelium-dependent coronary 
vasodilation after a single LDL apheresis in patients with hypercholesterolemia. J Clin Apher 
2004;19:11–6. [PubMed: 15095396] 
12. Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by 
echocardiography in adults: an update from the American Society of Echocardiography and the 
European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2015;28:1–39.e14. 
[PubMed: 25559473] 
13. Wei K, Jayaweera AR, Firoozan S, Linka A, Skyba DM, Kaul S. Quantification of myocardial 
blood flow with ultrasound-induced destruction of microbubbles administered as a constant venous 
infusion. Circulation 1998;97:473–83. [PubMed: 9490243] 
14. Pascotto M, Leong-Poi H, Kaufmann B, et al. Assessment of ischemia-induced microvascular 
remodeling using contrast-enhanced ultrasound vascular anatomic mapping. J Am Soc 
Echocardiogr 2007;20:1100–8. [PubMed: 17566703] 
15. Womack L, Peters D, Barrett EJ, Kaul S, Price W, Lindner JR. Abnormal skeletal muscle capillary 
recruitment during exercise in patients with type 2 diabetes mellitus and microvascular 
complications. J Am Coll Cardiol 2009;53: 2175–83. [PubMed: 19497445] 
16. Stapleton PA, Goodwill AG, James ME, Brock RW, Frisbee JC. Hypercholesterolemia and 
microvascular dysfunction: interventional strategies. J Inflamm (Lond) 2010;7:54. [PubMed: 
21087503] 
17. Feron O, Dessy C, Moniotte S, Desager JP, Balligand JL. Hypercholesterolemia decreases nitric 
oxide production by promoting the interaction of caveolin and endothelial nitric oxide synthase. J 
Clin Invest 1999;103:897–905. [PubMed: 10079111] 
18. Cardillo C, Kilcoyne CM, Cannon RO 3rd, Panza JA. Increased activity of endogenous endothelin 
in patients with hypercholesterolemia. J Am Coll Cardiol 2000;36:1483–8. [PubMed: 11079646] 
19. Jay RH, Rampling MW, Betteridge DJ. Abnormalities of blood rheology in familial 
hypercholesterolaemia: effects of treatment. Atherosclerosis 1990;85:249–56. [PubMed: 2129320] 
20. Duncker DJ, Koller A, Merkus D, Canty JM Jr. Regulation of coronary blood flow in health and 
ischemic heart disease. Prog Cardiovasc Dis 2015; 57:409–22. [PubMed: 25475073] 
21. Pries AR, Secomb TW, Gaehtgens P. Biophysical aspects of blood flow in the microvasculature. 
Cardiovasc Res 1996;32:654–67. [PubMed: 8915184] 
22. Rim SJ, Leong-Poi H, Lindner JR, Wei K, Fisher NG, Kaul S. Decrease in coronary blood flow 
reserve during hyperlipidemia is secondary to an increase in blood viscosity. Circulation 2001;104: 
2704–9. [PubMed: 11723023] 
23. Wei K, Le E, Bin JP, Coggins M, Jayawera AR, Kaul S. Mechanism of reversible (99m)Tc-
sestamibi perfusion defects during pharmacologically induced vasodilatation. Am J Physiol Heart 
Circ Physiol 2001;280:H1896–904. [PubMed: 11247807] 
24. Potter RF, Groom AC. Capillary diameter and geometry in cardiac and skeletal muscle studied by 
means of corrosion casts. Microvasc Res 1983; 25:68–84. [PubMed: 6835100] 
25. Tamai O, Matsuoka H, Itabe H, Wada Y, Kohno K, Imaizumi T. Single LDL apheresis improves 
endothelium-dependent vasodilatation in hypercholesterolemic humans. Circulation 1997; 95:76–
82. [PubMed: 8994420] 
Wu et al. Page 10
JACC Cardiovasc Imaging. Author manuscript; available in PMC 2020 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
26. Sarelius I, Pohl U. Control of muscle blood flow during exercise: local factors and integrative 
mechanisms. Acta Physiol (Oxf) 2010;199:349–65. [PubMed: 20353492] 
27. Teragawa H, Ueda K, Matsuda K, et al. Relationship between endothelial function in the coronary 
and brachial arteries. Clin Cardiol 2005;28: 460–6. [PubMed: 16274093] 
28. Ferrer M, Encabo A, Conde MV, Marin J, Balfagon G. Heterogeneity of endothelium-dependent 
mechanisms in different rabbit arteries. J Vasc Res 1995;32:339–46. [PubMed: 7578802] 
29. Penny WF, Ben-Yehuda O, Kuroe K, et al. Improvement of coronary artery endothelial dysfunction 
with lipid-lowering therapy: heterogeneity of segmental response and correlation with plasma-
oxidized low density lipoprotein. J Am Coll Cardiol 2001;37:766–74. [PubMed: 11693750] 
30. Khan TZ, Hsu LY, Arai AE, et al. Apheresis as novel treatment for refractory angina with raised 
lipoprotein(a): a randomized controlled cross-over trial. Eur Heart J 2017;38:1561–9. [PubMed: 
28453721] 
31. Hartikainen J, Hassinen I, Hedman A, et al. Adenoviral intramyocardial VEFG-DdNdC gene 
transfer increases myocardial perfusion reserve in refractory angina patients: a phase I/IIa study 
with 1 year follow-up. Eur Heart J 2017;38: 2547–55. [PubMed: 28903476] 
Wu et al. Page 11
JACC Cardiovasc Imaging. Author manuscript; available in PMC 2020 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
Apheresis can result in an immediate improvement in myocardial perfusion in patients 
with FH in whom maximal medical therapy has not achieved targeted lipid lowering.
TRANSLATIONAL OUTLOOK:
Treatments that acutely correct hyperlipidemia can increase resting myocardial blood 
flow independent of changes in myocardial work.
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FIGURE 1. Plasma Lipoprotein Lipid Measurements in Subjects Pre- and Post-Apheresis
Individual values are illustrated for patients on chronic apheresis (green) and those 
undergoing apheresis for the first time (pink). *p < 0.01 versus pre-apheresis. †p < 0.05 
versus pre-apheresis. See text for mean values. HDL = high-density lipoprotein; LDL = low-
density lipoprotein; OxPL-apoB = oxidized phospholipid on apolipoprotein B-100; VLDL = 
very low-density lipoprotein.
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FIGURE 2. Blood Characteristics Influencing Microvascular Rheology
Mean ± SEM values for plasma viscosity are shown for rotational shear of (A) 75 s−1 and 
(B) 150 s−1. (C) Mean ± SEM values for erythrocyte deformability. *p < 0.05 versus pre-
apheresis.
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FIGURE 3. Skeletal Muscle Perfusion Imaging Data
Box-and-whisker plots for median (bar), 25% to 75% confidence interval (box), and range 
(whiskers) of values for resting skeletal muscle contrast-enhanced ultrasound data 
depicting: (A) microvascular blood flow, (B) blood flux rate or β, and (C) microvascular 
blood volume (MBV). Data from 1 outlying individual with extremely high resting β was 
removed after performing Grubb’s test for outliers. (D to F) Similar plots are illustrated for 
skeletal muscle during contractile exercise. p = NS for all pre- versus post-apheresis values. 
IU = video intensity units.
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FIGURE 4. Myocardial Perfusion Imaging Data
Box-and-whisker plots are depicted for myocardial contrast echocardiography data on (A) 
microvascular blood flow, (B) blood flux rate or β, and (C) microvascular blood volume 
(MBV) in the myocardium at rest. Individual changes are provided in Online Figure 2. (D) 
Background-subtracted color-coded myocardial contrast echocardiography images obtained 
at each sequential end-systole (left to right) after a high-power pulse sequence, and (E) time-
intensity data illustrating changes in resting myocardial perfusion from single subject who 
had a modest increase in perfusion after apheresis. IU = video intensity units.
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FIGURE 5. Lipid Variables and Myocardial Blood Flow
Correlations are shown for (A) OxPL on apo B-100 lipoproteins or (B) LDL cholesterol with 
myocardial perfusion on myocardial contrast echocardiography expressed as the 
microvascular blood flux rate (β). Data are combined for pre-apheresis (green) and post-
apheresis (pink) stages. SEE = standard error of the estimate; other abbreviations as in 
Figure 1.
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FIGURE 6. Arterial Tension Assays and Endothelial NO Production
Tension assay dose-response curves illustrate degree of relaxation as a percentage of 
maximal tension (mean ± SEM) according to acetylcholine (Ach) concentration for the (A) 
coronary and (B) femoral branch arteries in a water bath containing pre- and post-apheresis 
plasma. For coronary analysis, p < 0.05 versus pre-apheresis by half maximal inhibitory 
concentration analysis. (C) Mean ± SEM values for 4,5-diaminofluorescein diacetate-2 
(DAF-2) fluorescence over time, reflecting nitric oxide (NO) production, in cultured 
SVEC4–10 endothelial cells exposed to plasma from healthy volunteers or familial 
hypercholesterolemia patients pre- and post-apheresis. (D) Mean ± SEM area under the 
curve (AUC) for 10-min acquisition. *p < 0.05 versus healthy control subjects.
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Table 1
Subject Demographics and Characteristics
Age, yrs 56 ± 11
Male/female 2/6
Body mass index, kg/m2 31.8 ± 5.8
First apheresis 3 (38)
Days since last apheresis* 28 (17–37)
Number of preceding apheresis sessions* 60 (16–129)
Diabetes 1 (13)
Hypertension 5 (63)
Smoking 1 (13)
Coronary revascularization 2 (25)
Myocardial infarction 2 (25)
Medications
 Statin 5 (63)
 Ezetimibe 3 (38)
 Bile acid sequestrant 1 (13)
 PCSK9 inhibitor 1 (13)
 Aspirin 6 (75)
 P2Y12 inhibitor 1 (13)
 ACE inhibitor or ARB 3 (38)
 Beta-blocker 6 (75)
 Calcium-channel blocker 2 (25)
Values are mean ± SD, n, n (%), or median (95% confidence interval).
*
Data for non-first-time apheresis patients.
ACE = angiotensin-converting enzyme; ARB = angiotensin receptor blocker; PCSK9 = proprotein convertase subtilisin/kexin type-9.
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Table 2
Hemodynamic and Echocardiographic Data
Pre-Apheresis Post-Apheresis p Value*
Heart rate, min−1 76 ± 15 68 ± 9 0.10
Systolic BP, mm Hg 126 ± 16 128 ± 11 0.69
Diastolic BP, mm Hg 68 ± 11 71 ± 10 0.09
Double product, mm Hg/min 9,566 ± 2,186 8,744 ± 1,580 0.36
LVESV, ml 29.8 ± 19.0 26.9 ± 12.7 0.45
LVEDV, ml 88.2 ± 31.8 88.2 ± 36.5 0.99
LVEF, % 68.1 ± 11.0 66.5 ± 12.4 0.66
Stroke volume index, ml/m2 36.7 ± 8.9 34.7 ± 9.9 0.37
Myocardial work, (mm Hg · ml)/(m2·min) 5,832 ± 1,712 6,112 ± 1,678 0.59
EA, mm Hg/(ml· m2) 1.67 ± 0.51 1.84 ± 0.64 0.13
SVR, dynes ·s/cm5 1,226 ± 480 1,633 ± 710 0.07
Global longitudinal strain −16.9 ± 3.2 −18.2 ± 2.8 0.25
Values are mean ± SEM.
*
Pre- versus post-apheresis.
BP = blood pressure; Ea = arterial elastance; Ees = end-systolic left ventricular elastance; LVEF = left ventricular ejection fraction; LVEDV = left 
ventricular end-diastolic volume; LVESV = left ventricular end-systolic volume; SVR = systemic vascular resistance.
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